USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS
Clinical trials have provided evidence for the efficacy of tocilizumab (TCZ) used alone and in combination with basic anti-inflammatory drugs in patients with rheumatoid arthritis (RA). TCZ therapy has been found to considerably alleviate the clinical manifestations of RA, improves joint function an...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2010-03-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/273 |
| _version_ | 1826557063240613888 |
|---|---|
| author | E L Nasonov E Yu Panasyuk E L Nasonov E Yu Panasyuk |
| author_facet | E L Nasonov E Yu Panasyuk E L Nasonov E Yu Panasyuk |
| author_sort | E L Nasonov |
| collection | DOAJ |
| description | Clinical trials have provided evidence for the efficacy of tocilizumab (TCZ) used alone and in combination with basic anti-inflammatory drugs in patients with rheumatoid arthritis (RA). TCZ therapy has been found to considerably alleviate the clinical manifestations of RA, improves joint function and quality of life, and retards joint destruction and radiographic disease progression. TCZ has been noted to demonstrate good results in the treatment of patients with the prolonged disease and a history of inefficient tumor necrosis factor-〈 inhibitors. |
| first_indexed | 2024-04-10T02:09:11Z |
| format | Article |
| id | doaj.art-f81e4b98cad24afd91253b9b3f289f79 |
| institution | Directory Open Access Journal |
| issn | 1996-7012 2310-158X |
| language | Russian |
| last_indexed | 2025-03-14T08:22:38Z |
| publishDate | 2010-03-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj.art-f81e4b98cad24afd91253b9b3f289f792025-03-02T13:10:53ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2010-03-0141596110.14412/1996-7012-2010-5881578USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITISE L NasonovE Yu PanasyukE L NasonovE Yu PanasyukClinical trials have provided evidence for the efficacy of tocilizumab (TCZ) used alone and in combination with basic anti-inflammatory drugs in patients with rheumatoid arthritis (RA). TCZ therapy has been found to considerably alleviate the clinical manifestations of RA, improves joint function and quality of life, and retards joint destruction and radiographic disease progression. TCZ has been noted to demonstrate good results in the treatment of patients with the prolonged disease and a history of inefficient tumor necrosis factor-〈 inhibitors.https://mrj.ima-press.net/mrj/article/view/273rheumatoid arthritisgenetic engineering biological agentstocilizumab |
| spellingShingle | E L Nasonov E Yu Panasyuk E L Nasonov E Yu Panasyuk USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS Современная ревматология rheumatoid arthritis genetic engineering biological agents tocilizumab |
| title | USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS |
| title_full | USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS |
| title_fullStr | USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS |
| title_full_unstemmed | USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS |
| title_short | USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS |
| title_sort | use of the new genetic engineering biological agent tocilizumabin the treatment of rheumatoid arthritis |
| topic | rheumatoid arthritis genetic engineering biological agents tocilizumab |
| url | https://mrj.ima-press.net/mrj/article/view/273 |
| work_keys_str_mv | AT elnasonov useofthenewgeneticengineeringbiologicalagenttocilizumabinthetreatmentofrheumatoidarthritis AT eyupanasyuk useofthenewgeneticengineeringbiologicalagenttocilizumabinthetreatmentofrheumatoidarthritis AT elnasonov useofthenewgeneticengineeringbiologicalagenttocilizumabinthetreatmentofrheumatoidarthritis AT eyupanasyuk useofthenewgeneticengineeringbiologicalagenttocilizumabinthetreatmentofrheumatoidarthritis |